Sheng Pu Pharmaceutics

Shengpu Pharmaceutics is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of high-end formulations and innovative small molecule drugs. The company leverages its proprietary nanocrystal and solubilization platforms to improve the therapeutic performance of established drugs, primarily through the 505(b)(2) regulatory pathway. Its pipeline focuses on critical therapeutic areas including oncology, the central nervous system, and anesthesia. Shengpu's lead products include optimized versions of docetaxel and aprepitant, designed to offer better safety and efficacy profiles than existing standards of care. The firm is supported by prominent venture capital investors and is led by a team with deep expertise in pharmaceutical science and global regulatory standards. Shengpu aims to bridge the gap between innovative drug discovery and clinical application through advanced drug delivery technologies.